Join us for a Pink Ribbon Walk this spring Choose from 4 incredible walks, each in an iconic destination surrounded by spectacular scenery. 10 or 20 mile options are available.
Book a Public Health Talk Raise awareness of breast cancer in your local community or network by booking a free online or in-person talk.
Home About us Media Breast Cancer Now media statements 193 results We respond to NICE decision to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS 25 Feb 2022 2 min read We respond to today's NHSE Breast Screening Programme 2020-21 report 24 Feb 2022 2 min read We respond to the latest COVID-19 guidance 22 Feb 2022 1 min read We respond to a new study looking at breast pain and breast cancer 22 Feb 2022 1 min read We respond to 'The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation’ 15 Feb 2022 1 min read We respond to NHS England breast cancer waiting times: December 2021 10 Feb 2022 1 min read Responding to new research that pembrolizumab cuts the risk of triple negative breast cancer returning by 37% 10 Feb 2022 1 min read We respond to House of Commons library analysis revealing record numbers of women facing delays to see an NHS cancer specialist 07 Feb 2022 1 min read We respond to Professor Gilbert’s talk at UK Interdisciplinary Breast Cancer Symposium, surrounding ‘Personalised breast cancer screening’ 31 Jan 2022 1 min read Responding to a new AI tool being tested to establish HER2 status in breast cancer 19 Jan 2022 1 min read We welcome the SMC’s approval of two new treatments for use on the NHS in Scotland- trastuzumab deruxtecan (Enhertu) and tucatinib (Tukysa) in combination with trastuzumab and capecitabine 17 Jan 2022 3 min read We respond to NHS England breast cancer waiting times: November 2021 13 Jan 2022 2 min read Previous 1 ... 11 ... 17 Next
We respond to NICE decision to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS 25 Feb 2022 2 min read
We respond to 'The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation’ 15 Feb 2022 1 min read
Responding to new research that pembrolizumab cuts the risk of triple negative breast cancer returning by 37% 10 Feb 2022 1 min read
We respond to House of Commons library analysis revealing record numbers of women facing delays to see an NHS cancer specialist 07 Feb 2022 1 min read
We respond to Professor Gilbert’s talk at UK Interdisciplinary Breast Cancer Symposium, surrounding ‘Personalised breast cancer screening’ 31 Jan 2022 1 min read
Responding to a new AI tool being tested to establish HER2 status in breast cancer 19 Jan 2022 1 min read
We welcome the SMC’s approval of two new treatments for use on the NHS in Scotland- trastuzumab deruxtecan (Enhertu) and tucatinib (Tukysa) in combination with trastuzumab and capecitabine 17 Jan 2022 3 min read
